Mirati Therapeutics, Inc. Common Stock
MRTX
MRTX was delisted on the 22nd of January, 2024.
159 hedge funds and large institutions have $2.96B invested in Mirati Therapeutics, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 58 funds opening new positions, 53 increasing their positions, 37 reducing their positions, and 11 closing their positions.
427% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 11
103% more call options, than puts
Call options by funds: $66.1M | Put options by funds: $32.6M
100% more capital invested
Capital invested by funds: $1.48B → $2.96B (+$1.48B)
43% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 37
42% more funds holding
Funds holding: 112 → 159 (+47)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$164M |
| 2 |
PA
Perceptive Advisors
New York
|
+$70.6M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$65M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$51M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$33.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$63.6M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$46M |
| 3 |
DM
Deerfield Management
New York
|
-$42.3M |
| 4 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$19.4M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
-$17.5M |
MRTX Hedge Fund Activity: Q1 2019 in Review
159 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Mirati Therapeutics, Inc. Common Stock (MRTX) for Q1 2019, worth a combined $2.96B — up 100% from $1.48B a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new MRTX positions and 11 closed out — a net gain of 47 holders — while 53 added to existing stakes and 37 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $164M. The largest seller was Avoro Capital Advisors, cutting an estimated $63.6M.
- 159 institutional investors held Mirati Therapeutics, Inc. Common Stock (MRTX) as of Q1 2019, up from 112 in Q4 2018.
- Funds reported $2.96B of Mirati Therapeutics, Inc. Common Stock stock for Q1 2019, up 100% quarter-over-quarter.
- 58 funds opened new Mirati Therapeutics, Inc. Common Stock positions in Q1 2019 and 11 closed out, a net change of +47 holders.
- The largest Mirati Therapeutics, Inc. Common Stock buyer in Q1 2019 was Fidelity Investments, an estimated $164M added.
- The largest Mirati Therapeutics, Inc. Common Stock seller in Q1 2019 was Avoro Capital Advisors, an estimated $63.6M sold.
Based on aggregated 13F filings for Q1 2019.